Gilead Sciences and Merck & Co. Deliver Positive ISLEND Phase 3 Results
FOSTER CITY, Calif. & RAHWAY, N.J., July 22, 2026 Gilead Sciences and Merck announced detailed results from the Phase...
AI drug discovery artificial intelligence Autoimmune Disease Bio-Pharma biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
FOSTER CITY, Calif. & RAHWAY, N.J., July 22, 2026 Gilead Sciences and Merck announced detailed results from the Phase...
FOSTER CITY, Calif., July 22, 2026 Gilead Sciences announced an extensive scientific program for the 26th International AIDS Conference...
Rahway, New Jersey, USA – April 21, 2026 In a major breakthrough for HIV therapeutics, Merck has received U.S....
